NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Lixte Biotechnology Holdings, Inc. (LIXT) Stock Analysis

Lixte Biotechnology Holdings, Inc. (LIXT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LIXT

$3.71

−$0.39 (−9.51%)

Sep 2, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LIXT with… →

LIXT Key Statistics

As of Sep 2, 2026
Trading
Open
$4.06
Previous Close
$4.10
Day's Range
3.67–4.19
52-Week Range
0.64–6.26
Volume
387.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$69.96M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.15
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.01M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−10.39%
Dividend and dates
Avg Volume
56.36K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LIXT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−5.60%
2025+63.07%

As of September 2, 2026.

LIXT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.01M—
2024$0.00−$3.59M—
2023$0.00−$5.09M—
2022$0.00−$6.31M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$5.11M−$6.01M—
2024$0.00—−$3.57M−$3.59M—
2023$0.00—−$5.09M−$5.09M—
2022$0.00—−$6.31M−$6.31M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LIXT Valuation vs Biotechnology Median

Median of 656 stocks
MetricLIXTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Lixte Biotechnology Holdings, Inc. (LIXT) at $69.96M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 3.

LIXT last closed at $3.71 on September 2, 2026. That is −$0.39 (−9.51%) against the previous close. The 52-week range on file runs from $0.64 to $6.26. The latest close sits 479.69% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $6.01M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.15.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −10.39%. The stored price history starts on January 13, 2025, and the total return since then is +53.94%. The reported beta is 1.05. Daily returns over the trailing 1 year annualize to a volatility of 91.44%.

Growth & Income

No dividend is on file for LIXT.

2026 is still running; the price is −5.60% year to date. The record holds one complete calendar year, 2025, which returned +63.07%.

Peer Comparison

Lixte Biotechnology Holdings, Inc. (LIXT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lixte Biotechnology Holdings, Inc. LIXT $69.96M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Lixte Biotechnology Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 2, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.

Visit website →